Gearing Up to Challenge Pfizer in a Rare Disease, BridgeBio Secures Up to $1.25B

Retrieved on: 2024-01-18 22:54:34

Tags for this article:

Click the tags to see associated articles and topics

Gearing Up to Challenge Pfizer in a Rare Disease, BridgeBio Secures Up to $1.25B. View article details on hiswai:

Excerpt

The drug is intended to reduce protein buildup in tissue and organs. Vyndaqel, Pfizer's ATTR cardiomyopathy drug, is also a transthyretin stabilizer.

Article found on: medcitynews.com